+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Non-insulin Diabetes Therapeutics Market 2023-2027

  • PDF Icon

    Report

  • 172 Pages
  • May 2023
  • Region: Global
  • TechNavio
  • ID: 5351697
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The non-insulin diabetes therapeutics market is forecasted to grow by USD 31251.55 mn during 2022-2027, accelerating at a CAGR of 10.82% during the forecast period. The report on the non-insulin diabetes therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by an increasing number of people with type 2 diabetes, the growing prevalence of diabetes among people aged 6-19 and 35-50, and recent product approvals.

The non-insulin diabetes therapeutics market is segmented as below:

By Type

  • DPP4 inhibitors
  • GLP-1 receptor agonists
  • SGLT2 inhibitors
  • Others

By Distribution Channel

  • Offline
  • Online

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the innovations in therapies as one of the prime reasons driving the non-insulin diabetes therapeutics market growth during the next few years. Also, strategic alliances between vendors and increasing demand for combination drugs will lead to sizable demand in the market.

The report on the non-insulin diabetes therapeutics market covers the following areas:

  • Non-insulin diabetes therapeutics market sizing
  • Non-insulin diabetes therapeutics market forecast
  • Non-insulin diabetes therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-insulin diabetes therapeutics market vendors that include Abbott Laboratories, AstraZeneca PLC, Better Therapeutics Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and The Cleveland Clinic Foundation. Also, the non-insulin diabetes therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global non-insulin diabetes therapeutics market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global non-insulin diabetes therapeutics market 2017 - 2021 ($ million)
4.2 Type Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
4.3 Distribution Channel Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Type
6.1 Market segments
Exhibit 30: Chart on Type - Market share 2022-2027 (%)
Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 DPP4 inhibitors - Market size and forecast 2022-2027
Exhibit 34: Chart on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
6.4 GLP-1 receptor agonists - Market size and forecast 2022-2027
Exhibit 38: Chart on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
6.5 SGLT2 inhibitors - Market size and forecast 2022-2027
Exhibit 42: Chart on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
6.6 Others - Market size and forecast 2022-2027
Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
6.7 Market opportunity by Type
Exhibit 50: Market opportunity by Type ($ million)
Exhibit 51: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 52: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibit 53: Data Table on Distribution Channel - Market share 2022-2027 (%)
7.2 Comparison by Distribution Channel
Exhibit 54: Chart on Comparison by Distribution Channel
Exhibit 55: Data Table on Comparison by Distribution Channel
7.3 Offline - Market size and forecast 2022-2027
Exhibit 56: Chart on Offline - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Offline - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Offline - Year-over-year growth 2022-2027 (%)
7.4 Online - Market size and forecast 2022-2027
Exhibit 60: Chart on Online - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Online - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Online - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Online - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Distribution Channel
Exhibit 64: Market opportunity by Distribution Channel ($ million)
Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 UK - Market size and forecast 2022-2027
Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.11 India - Market size and forecast 2022-2027
Exhibit 103: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on India - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ million)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 115: Abbott Laboratories - Overview
Exhibit 116: Abbott Laboratories - Business segments
Exhibit 117: Abbott Laboratories - Key news
Exhibit 118: Abbott Laboratories - Key offerings
Exhibit 119: Abbott Laboratories - Segment focus
12.4 AstraZeneca PLC
Exhibit 120: AstraZeneca PLC - Overview
Exhibit 121: AstraZeneca PLC - Product / Service
Exhibit 122: AstraZeneca PLC - Key news
Exhibit 123: AstraZeneca PLC - Key offerings
12.5 Better Therapeutics Inc.
Exhibit 124: Better Therapeutics Inc. - Overview
Exhibit 125: Better Therapeutics Inc. - Product / Service
Exhibit 126: Better Therapeutics Inc. - Key news
Exhibit 127: Better Therapeutics Inc. - Key offerings
12.6 Boehringer Ingelheim International GmbH
Exhibit 128: Boehringer Ingelheim International GmbH - Overview
Exhibit 129: Boehringer Ingelheim International GmbH - Business segments
Exhibit 130: Boehringer Ingelheim International GmbH - Key news
Exhibit 131: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 132: Boehringer Ingelheim International GmbH - Segment focus
12.7 Eli Lilly and Co.
Exhibit 133: Eli Lilly and Co. - Overview
Exhibit 134: Eli Lilly and Co. - Product / Service
Exhibit 135: Eli Lilly and Co. - Key news
Exhibit 136: Eli Lilly and Co. - Key offerings
12.8 F. Hoffmann La Roche Ltd.
Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 142: GlaxoSmithKline Plc - Overview
Exhibit 143: GlaxoSmithKline Plc - Business segments
Exhibit 144: GlaxoSmithKline Plc - Key news
Exhibit 145: GlaxoSmithKline Plc - Key offerings
Exhibit 146: GlaxoSmithKline Plc - Segment focus
12.10 Johnson and Johnson Services Inc.
Exhibit 147: Johnson and Johnson Services Inc. - Overview
Exhibit 148: Johnson and Johnson Services Inc. - Business segments
Exhibit 149: Johnson and Johnson Services Inc. - Key news
Exhibit 150: Johnson and Johnson Services Inc. - Key offerings
Exhibit 151: Johnson and Johnson Services Inc. - Segment focus
12.11 Merck KGaA
Exhibit 152: Merck KGaA - Overview
Exhibit 153: Merck KGaA - Business segments
Exhibit 154: Merck KGaA - Key news
Exhibit 155: Merck KGaA - Key offerings
Exhibit 156: Merck KGaA - Segment focus
12.12 Novartis AG
Exhibit 157: Novartis AG - Overview
Exhibit 158: Novartis AG - Business segments
Exhibit 159: Novartis AG - Key offerings
Exhibit 160: Novartis AG - Segment focus
12.13 Novo Nordisk AS
Exhibit 161: Novo Nordisk AS - Overview
Exhibit 162: Novo Nordisk AS - Business segments
Exhibit 163: Novo Nordisk AS - Key offerings
Exhibit 164: Novo Nordisk AS - Segment focus
12.14 Pfizer Inc.
Exhibit 165: Pfizer Inc. - Overview
Exhibit 166: Pfizer Inc. - Product / Service
Exhibit 167: Pfizer Inc. - Key news
Exhibit 168: Pfizer Inc. - Key offerings
12.15 Sanofi SA
Exhibit 169: Sanofi SA - Overview
Exhibit 170: Sanofi SA - Business segments
Exhibit 171: Sanofi SA - Key news
Exhibit 172: Sanofi SA - Key offerings
Exhibit 173: Sanofi SA - Segment focus
12.16 Takeda Pharmaceutical Co. Ltd.
Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 176: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 177: Takeda Pharmaceutical Co. Ltd. - Key offerings
12.17 The Cleveland Clinic Foundation
Exhibit 178: The Cleveland Clinic Foundation - Overview
Exhibit 179: The Cleveland Clinic Foundation - Product / Service
Exhibit 180: The Cleveland Clinic Foundation - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 181: Inclusions checklist
Exhibit 182: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 183: Currency conversion rates for US$
13.4 Research methodology
Exhibit 184: Research methodology
Exhibit 185: Validation techniques employed for market sizing
Exhibit 186: Information sources
13.5 List of abbreviations
Exhibit 187: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 18: Historic Market Size - Data Table on global non-insulin diabetes therapeutics market 2017 - 2021 ($ million)
Exhibits 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
Exhibits 20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2022 and 2027
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 29: Chart on Market condition - Five forces 2022 and 2027
Exhibits 30: Chart on Type - Market share 2022-2027 (%)
Exhibits 31: Data Table on Type - Market share 2022-2027 (%)
Exhibits 32: Chart on Comparison by Type
Exhibits 33: Data Table on Comparison by Type
Exhibits 34: Chart on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits 35: Data Table on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits 36: Chart on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits 37: Data Table on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits 38: Chart on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
Exhibits 39: Data Table on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
Exhibits 40: Chart on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
Exhibits 41: Data Table on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
Exhibits 42: Chart on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits 43: Data Table on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits 44: Chart on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits 45: Data Table on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibits 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibits 48: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibits 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
Exhibits 50: Market opportunity by Type ($ million)
Exhibits 51: Data Table on Market opportunity by Type ($ million)
Exhibits 52: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibits 53: Data Table on Distribution Channel - Market share 2022-2027 (%)
Exhibits 54: Chart on Comparison by Distribution Channel
Exhibits 55: Data Table on Comparison by Distribution Channel
Exhibits 56: Chart on Offline - Market size and forecast 2022-2027 ($ million)
Exhibits 57: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
Exhibits 58: Chart on Offline - Year-over-year growth 2022-2027 (%)
Exhibits 59: Data Table on Offline - Year-over-year growth 2022-2027 (%)
Exhibits 60: Chart on Online - Market size and forecast 2022-2027 ($ million)
Exhibits 61: Data Table on Online - Market size and forecast 2022-2027 ($ million)
Exhibits 62: Chart on Online - Year-over-year growth 2022-2027 (%)
Exhibits 63: Data Table on Online - Year-over-year growth 2022-2027 (%)
Exhibits 64: Market opportunity by Distribution Channel ($ million)
Exhibits 65: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 69: Chart on Geographic comparison
Exhibits 70: Data Table on Geographic comparison
Exhibits 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits 90: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits 97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits 98: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 101: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits 103: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibits 104: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibits 105: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibits 106: Data Table on India - Year-over-year growth 2022-2027 (%)
Exhibits 107: Market opportunity By Geographical Landscape ($ million)
Exhibits 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 109: Impact of drivers and challenges in 2022 and 2027
Exhibits 110: Overview on Criticality of inputs and Factors of differentiation
Exhibits 111: Overview on factors of disruption
Exhibits 112: Impact of key risks on business
Exhibits 113: Vendors covered
Exhibits 114: Matrix on vendor position and classification
Exhibits 115: Abbott Laboratories - Overview
Exhibits 116: Abbott Laboratories - Business segments
Exhibits 117: Abbott Laboratories - Key news
Exhibits 118: Abbott Laboratories - Key offerings
Exhibits 119: Abbott Laboratories - Segment focus
Exhibits 120: AstraZeneca PLC - Overview
Exhibits 121: AstraZeneca PLC - Product / Service
Exhibits 122: AstraZeneca PLC - Key news
Exhibits 123: AstraZeneca PLC - Key offerings
Exhibits 124: Better Therapeutics Inc. - Overview
Exhibits 125: Better Therapeutics Inc. - Product / Service
Exhibits 126: Better Therapeutics Inc. - Key news
Exhibits 127: Better Therapeutics Inc. - Key offerings
Exhibits 128: Boehringer Ingelheim International GmbH - Overview
Exhibits 129: Boehringer Ingelheim International GmbH - Business segments
Exhibits 130: Boehringer Ingelheim International GmbH - Key news
Exhibits 131: Boehringer Ingelheim International GmbH - Key offerings
Exhibits 132: Boehringer Ingelheim International GmbH - Segment focus
Exhibits 133: Eli Lilly and Co. - Overview
Exhibits 134: Eli Lilly and Co. - Product / Service
Exhibits 135: Eli Lilly and Co. - Key news
Exhibits 136: Eli Lilly and Co. - Key offerings
Exhibits 137: F. Hoffmann La Roche Ltd. - Overview
Exhibits 138: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 139: F. Hoffmann La Roche Ltd. - Key news
Exhibits 140: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 141: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 142: GlaxoSmithKline Plc - Overview
Exhibits 143: GlaxoSmithKline Plc - Business segments
Exhibits 144: GlaxoSmithKline Plc - Key news
Exhibits 145: GlaxoSmithKline Plc - Key offerings
Exhibits 146: GlaxoSmithKline Plc - Segment focus
Exhibits 147: Johnson and Johnson Services Inc. - Overview
Exhibits 148: Johnson and Johnson Services Inc. - Business segments
Exhibits 149: Johnson and Johnson Services Inc. - Key news
Exhibits 150: Johnson and Johnson Services Inc. - Key offerings
Exhibits 151: Johnson and Johnson Services Inc. - Segment focus
Exhibits 152: Merck KGaA - Overview
Exhibits 153: Merck KGaA - Business segments
Exhibits 154: Merck KGaA - Key news
Exhibits 155: Merck KGaA - Key offerings
Exhibits 156: Merck KGaA - Segment focus
Exhibits 157: Novartis AG - Overview
Exhibits 158: Novartis AG - Business segments
Exhibits 159: Novartis AG - Key offerings
Exhibits 160: Novartis AG - Segment focus
Exhibits 161: Novo Nordisk AS - Overview
Exhibits 162: Novo Nordisk AS - Business segments
Exhibits 163: Novo Nordisk AS - Key offerings
Exhibits 164: Novo Nordisk AS - Segment focus
Exhibits 165: Pfizer Inc. - Overview
Exhibits 166: Pfizer Inc. - Product / Service
Exhibits 167: Pfizer Inc. - Key news
Exhibits 168: Pfizer Inc. - Key offerings
Exhibits 169: Sanofi SA - Overview
Exhibits 170: Sanofi SA - Business segments
Exhibits 171: Sanofi SA - Key news
Exhibits 172: Sanofi SA - Key offerings
Exhibits 173: Sanofi SA - Segment focus
Exhibits 174: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibits 175: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibits 176: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibits 177: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibits 178: The Cleveland Clinic Foundation - Overview
Exhibits 179: The Cleveland Clinic Foundation - Product / Service
Exhibits 180: The Cleveland Clinic Foundation - Key offerings
Exhibits 181: Inclusions checklist
Exhibits 182: Exclusions checklist
Exhibits 183: Currency conversion rates for US$
Exhibits 184: Research methodology
Exhibits 185: Validation techniques employed for market sizing
Exhibits 186: Information sources
Exhibits 187: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global non-insulin diabetes therapeutics market: Abbott Laboratories, AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, and Sanofi SA.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is recent product approvals.'

According to the report, one of the major drivers for this market is the increasing number of people with type 2 diabetes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • AstraZeneca PLC
  • Better Therapeutics Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • The Cleveland Clinic Foundation